Intravitreal injection of KH902 — Competitive Intelligence Brief

Intravitreal injection of KH902 (Intravitreal injection of KH902) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (recombinant fusion protein). Area: Ophthalmology.

phase 2 VEGF inhibitor (recombinant fusion protein) VEGF-A, VEGF-B Ophthalmology Biologic

Target snapshot

Intravitreal injection of KH902 (Intravitreal injection of KH902) — Chengdu Kanghong Biotech Co., Ltd.. KH902 is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF) signaling to reduce abnormal blood vessel growth and vascular permeability in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravitreal injection of KH902 TARGET	Intravitreal injection of KH902	Chengdu Kanghong Biotech Co., Ltd.	phase 2	VEGF inhibitor (recombinant fusion protein)	VEGF-A, VEGF-B
Aflibercept Injection [Eylea]	Aflibercept Injection [Eylea]	Caregen Co. Ltd.	marketed	VEGF inhibitor (soluble decoy receptor)	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Aflibercept Intravitreous Injection	Aflibercept Intravitreous Injection	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (placental growth factor)
Intravitreal Aflibercept Injection	Intravitreal Aflibercept Injection	Ophthalmic Consultants of Boston	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Rescue Intravitreal Aflibercept Injection	Rescue Intravitreal Aflibercept Injection	Southeast Retina Center, Georgia	marketed	VEGF inhibitor / Recombinant fusion protein	VEGF-A, VEGF-B, PlGF (placental growth factor)
Aflibercept (Eylea)	Aflibercept (Eylea)	Ahmad Zeeshan Jamil	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Ziv aflibercept	Ziv aflibercept	Marashi Eye Clinic	marketed	VEGF inhibitor / Antiangiogenic agent	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (recombinant fusion protein) class)

1. Chengdu Kanghong Biotech Co., Ltd. · 1 drug in this class